Navigation Links
Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
Date:9/18/2007

pon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 1 and Phase 2 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, Pharmacopeia's ability to successfully perform under its collaborations with Cephalon, GlaxoSmithKline, Organon and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... 2011 Omnicell, Inc . (NASDAQ: ... and supply management solutions and analytics software for ... Hospital (RVH) selected Omnicell G4 solutions to ... Omnicell,s hallmark flexibility and functionality, RVH became the ...
... 26, 2011 PolyGel, the manufacturer of Orthopedic, ... long term exclusive distribution agreement with China National ... in Beijing, China, Sinopharm Foreign Trade is a ... (SINOPHARM Group). (Photo:   http://photos.prnewswire.com/prnh/20110726/NY40954 ...
Cached Medicine Technology:Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 2Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 3Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 4PolyGel Signs Long Term Exclusive Agreement With China's Largest Distributor of Healthcare Products 2
(Date:4/18/2014)... Harvard neuroscientists have made a discovery that turns 160 ... electrical insulating material long known to be essential for ... nerve cells, is not as ubiquitous as thought, according ... of the Harvard Stem Cell Institute (HSCI) and the ... collaboration with Professor Jeff Lichtman, of Harvard,s Department of ...
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... This news release is available in French . ... breakthrough could revolutionize surgical practice and regenerative medicine. A ... Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ... and Paris 13), has just demonstrated that the principle ... used in vivo to repair soft-tissue organs and tissues. ...
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... at Jefferson have found a mechanism by which a ... makes breast cancer more aggressive. Publishing in the ... prolactin, a pituitary hormone that normally stimulates breast development ... oncogene called BCL6. The BCL6 protein has previously been ...
... Predictive, Preventive and Personalised Medicine have founded, as the ... Creating a reliable scientific platform for the optimal combination ... laboratory medicine, the EPMA Journal will highlight ... and personalised medicine. The EPMA Journal ...
... , CARROLLTON, Texas , Feb. ... (AAUCM) has begun a sponsorship of the A-Claim™ medical payment ... , A-Claim ( www.A-Claim.com ) is a proprietary medical payment ... Carrollton, Texas , that is changing the way physicians, hospitals ...
... Nixon declared a "War on Cancer," the disease still claims ... expenditure of $5 billion by the U.S. government on research ... made since Nixon,s call to action in 1971, cancer research ... which is only increasing as scientists discover new drugs and ...
... ... As Strauss Radio Strategies continues to grow and expand, it has ... signing onto the GSA Schedule - the federal government procurement system. Government ... base and the addition to the GSA schedule will greatly facilitate the ...
... ... , ... February 3, 2010 -- Governance, Risk and Compliance (GRC) leader MetricStream ... over 2008 combined with record profits. MetricStream’s growth was fueled by companies prioritizing their need ...
Cached Medicine News:Health News:Springer publishes new journal in predictive, preventive and personalized medicine 2Health News:Urgent Care Providers Tout Benefits of A-Claim Medical Payment Solution 2Health News:Urgent Care Providers Tout Benefits of A-Claim Medical Payment Solution 3Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 2Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 3Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 4Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 5Health News:Strauss Radio Strategies - The Nation's Leading Radio Media Relations Firm - Expands Government Business with Award on GSA Schedule 2Health News:Strauss Radio Strategies - The Nation's Leading Radio Media Relations Firm - Expands Government Business with Award on GSA Schedule 3Health News:MetricStream Achieves Record Revenue Growth in 2009 with Global Customer Adoption of its Enterprise GRC Platform and Solutions 2Health News:MetricStream Achieves Record Revenue Growth in 2009 with Global Customer Adoption of its Enterprise GRC Platform and Solutions 3Health News:MetricStream Achieves Record Revenue Growth in 2009 with Global Customer Adoption of its Enterprise GRC Platform and Solutions 4
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
Shandon Paraffin Block Cabinet...
Medicine Products: